Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ViscoGel as Adjuvant in Act-HIB Vaccine
NCT01578070Phase 2Completed
- Sponsor
- Viscogel
- Start
- Mar 2012
- Primary completion
- Dec 2012
- Modality
- Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of ViscoGel in Haemophilus influenzae type b infection (Hib), sponsored by Viscogel. Started Mar 2012; status: completed.
02
Drugs
ViscoGel
03
Conditions
Haemophilus influenzae type b infection (Hib)
Beyond the preview
Go deeper on NCT01578070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01578070.